Journal article
Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics.
Timothy Papaluca, Stuart K Roberts, Simone I Strasser, Katherine A Stuart, Geoffrey Farrell, Gerry MacQuillan, Gregory J Dore, Amanda J Wade, Jacob George, Simon Hazeldine, James O'Beirne, Alan Wigg, Leslie Fisher, Bruce McGarity, Rohit Sawhney, Marie Sinclair, James Thomas, Ivan Valiozis, Martin Weltman, Mark Wilson Show all
Clinical Infectious Diseases | Published : 2020
DOI: 10.1093/cid/ciaa1318
Abstract
BACKGROUND: In clinical trials, HCV salvage treatment with Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) achieved an SVR12 rate of >95% in NS5A-experienced participants. Lower SVR12 rates have been reported in real-world studies, particularly for genotype (GT)3 infection and cirrhosis. We determined the efficacy and safety of SOF/VEL/VOX in a large real-world cohort. METHODS: We assessed the efficacy of salvage SOF/VEL/VOX for HCV infection in NS5A-inhibitor experienced participants with cirrhosis and portal hypertension, prior liver transplantation (LT) or severe extra-hepatic manifestations. SOF/VEL/VOX was available via an early access program. The primary outcome was SVR12. Secondary..
View full abstract